| __timestamp | Alnylam Pharmaceuticals, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 1213000 |
| Thursday, January 1, 2015 | 60610000 | 3425000 |
| Friday, January 1, 2016 | 89354000 | 6311000 |
| Sunday, January 1, 2017 | 199365000 | 9518000 |
| Monday, January 1, 2018 | 382359000 | 28080000 |
| Tuesday, January 1, 2019 | 479005000 | 36550000 |
| Wednesday, January 1, 2020 | 588420000 | 46125000 |
| Friday, January 1, 2021 | 620639000 | 68486000 |
| Saturday, January 1, 2022 | 770658000 | 92032000 |
| Sunday, January 1, 2023 | 795646000 | 117532000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Alnylam Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion strategy. In contrast, Rhythm Pharmaceuticals maintained a more conservative growth, with SG&A costs increasing by approximately 9,600% but from a much smaller base.
Alnylam's expenses peaked in 2023, reaching nearly 800 million, while Rhythm's expenses were about 15% of Alnylam's at the same time. This disparity highlights Alnylam's larger scale and broader market reach. However, Rhythm's leaner cost structure could offer a strategic advantage in niche markets. As both companies continue to evolve, their ability to manage these costs will be pivotal in determining their long-term success.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.